Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease

This study has been completed.
Cystic Fibrosis Foundation Therapeutics
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: March 6, 2003
Last updated: January 28, 2015
Last verified: January 2015